Literature DB >> 23352645

MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth.

Bisheng Zhou1, Ruihua Ma, Wenxia Si, Sisi Li, Yan Xu, Xin Tu, Qing Wang.   

Abstract

FGF2 and VEGFA are the two most potent angiogenic factors. Here we report that miR-503 can simultaneously down-regulate FGF2 and VEGFA. The expression of miR-503 is repressed in HCC cells and primary tumors due to a potential epigenetic mechanism. Overexpression of miR-503 reduced tumor angiogenesis in vitro and in vivo. We also found that miR-503 expression was down-regulated by hypoxia through HIF1α. These results identify a miRNA that targets both FGF2 and VEGFA in cancers, demonstrate the anti-angiogenesis role of miR-503 in tumorigenesis, and provide a novel mechanism for hypoxia-induced FGF2 and VEGFA through HIF1α-mediated inhibition of miR-503. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352645     DOI: 10.1016/j.canlet.2013.01.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  87 in total

Review 1.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

2.  Identification of a molecular signaling gene-gene regulatory network between GWAS susceptibility genes ADTRP and MIA3/TANGO1 for coronary artery disease.

Authors:  Chunyan Luo; Fan Wang; Xiang Ren; Tie Ke; Chengqi Xu; Bo Tang; Subo Qin; Yufeng Yao; Qiuyun Chen; Qing Kenneth Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-21       Impact factor: 5.187

3.  miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2).

Authors:  Xiao-hui Sun; Xiao-lin Geng; Jun Zhang; Chao Zhang
Journal:  Tumour Biol       Date:  2014-11-18

4.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

5.  αB-Crystallin Interacts with Nav1.5 and Regulates Ubiquitination and Internalization of Cell Surface Nav1.5.

Authors:  Yuan Huang; Zhijie Wang; Yinan Liu; Hongbo Xiong; Yuanyuan Zhao; Ling Wu; Chao Yuan; Longfei Wang; Yuxi Hou; Gang Yu; Zhengrong Huang; Chengqi Xu; Qiuyun Chen; Qing K Wang
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

6.  Post-transcriptional regulation of cardiac sodium channel gene SCN5A expression and function by miR-192-5p.

Authors:  Yuanyuan Zhao; Yuan Huang; Weihua Li; Zhijie Wang; Shaopeng Zhan; Mengchen Zhou; Yufeng Yao; Zhipeng Zeng; Yuxi Hou; Qiuyun Chen; Xin Tu; Qing K Wang; Zhengrong Huang
Journal:  Biochim Biophys Acta       Date:  2015-07-21

7.  Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.

Authors:  Lei Liu; Weiqing Qu; Zhaokun Zhong
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

8.  microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.

Authors:  Yuhua Chi; Feng Ding; Wenjie Zhang; Lifa Du
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

9.  Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.

Authors:  Zhuang Zuo; Sourindra Maiti; Shimin Hu; Sanam Loghavi; George A Calin; Guillermo Garcia-Manero; Hagop M Kantarjian; L Jeffrey Medeiros; Laurence J N Cooper; Carlos E Bueso-Ramos
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

10.  Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1.

Authors:  Wenxia Si; Wen Xie; Wenbing Deng; Yi Xiao; Sadashiva S Karnik; Chengqi Xu; Qiuyun Chen; Qing Kenneth Wang
Journal:  FASEB J       Date:  2018-04-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.